14th November 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Strides Pharma Science arm receives EMA approval for Osteoporosis drug

The pharma firm said that their biologics arm “Stelis Biopharma” received a positive feedback from the EMA (European Medicines Agency) granting market authorization for its first biosimilar product Kauliv.

Fake $8 twitter verification costs $15 Billion to pharma giant Eli Lily

A fake verified profile on Twitter impersonating the pharma bigshot “Eli Lily” tweeted a message announcing that they have made insulin free for all. The message spread like wildfire and sent the company’s stocks crashing. Lily clarified the issue later but the damage was done.

Aurobindo Pharma profit declines 41% to ₹409 Crore

On Saturday, Aurobindo Pharma reported a 41% drop in its consolidated net profit at ₹409 Crore for the Second Quarter ending on September 30, 2022. The revenue from operations also decreased to ₹5,739 crore in the September quarter.

Centre and Pharma companies working on pricing mechanisms for off-patent drugs

The Government authority and the Pharma companies are working on a pricing mechanism for drugs that are going off-patent soon. According to experts, this will create a predictable pricing regime for both the consumer and the manufacturer.

Aurobindo Pharma relives Director from his duty temporarily over arrest

After the arrest of Director Sarath Chandra Reddy in an alleged liquor scam that involved hundreds of crores of rupees, the board of directors of Aurobindo Pharmaceuticals Limited relieved him of his duties for now.

World's biggest Pharma cluster to be launched soon in Hyderabad

The largest Pharmaceutical cluster in the world is all set to be launched soon in the city of Hyderabad, Telangana. The 19,000 acres project has received all necessary approvals and clearances.

Anti-diabetes drugs and patented antivirals to get cheaper: NLEM

The government announced the release of the most recent NLEM (National List of Essential Medicines) in which 34 new drugs were added due to which Plenty of commonly used medications are predicted to become less expensive.

GSK's Oncology business suffers a blow with Zejula's setback

The British company stated on Friday that they are going to limit the use of its Ovarian Cancer drug in the US as a second treatment option, indicated to treat patients whose tumors contain specific mutations.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?